Health Care/Hospital

VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Admi...

2024-03-08 10:00 1155

Uniting for Women's Wellness on IWD - From China to Uzbekistan

- Interviewing Wang Leilei, the first blind model in China, and Viktoriya Tsay, head of Prenatal and Neonatal Medicine Department at Genscreen, BGI Genomics JV laboratory inUzbekistan. HONG KONG, March 8, 2024 /PRNewswire/ -- To mark International Women's Day (IWD), BGI Genomics interviewed Wang...

2024-03-08 08:07 2086

Pudu Robotics to Showcase Comprehensive Solutions at Australian Healthcare Week

SYDNEY, March 8, 2024 /PRNewswire/ -- Pudu Robotics ("PUDU"), the global leader in commercial service robots, is excited to announce its participation in the forthcoming Australian Healthcare Week (AHW), the biggest and most influential healthcare gathering in the southern hemisphere, scheduled f...

2024-03-08 08:00 2091

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items of...

2024-03-07 22:00 1171

P2G Foundation is Leading the Charge in Empowering Singapore's Homeless Population

SINGAPORE, March 7, 2024 /PRNewswire/ -- P2G Foundation announces its commitment to empowering lives and fostering hope forSingapore's unhoused population. With an unshakable commitment to extending support and creating pathways to opportunity, P2G Foundation emerges as a guiding light of compas...

2024-03-07 15:19 1859

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market inChina, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developi...

2024-03-07 15:04 1150

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and...

2024-03-07 11:53 2382

Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer HONG KONG and MACAO, March 7, 2024 /PRNewswire/ -- A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Phar...

2024-03-07 10:11 1903

A Global Milestone in Innovative Pancreatic Cancer Therapy

Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate. TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a memb...

2024-03-07 10:00 1707

Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance

CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- Epitomee® (TASE: EPIT) announced today that onFebruary 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in theUSA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally adm...

2024-03-07 09:00 1447

Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands

NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. OnDecember 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well ...

2024-03-06 21:37 1018

OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

--CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity-- NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innova...

2024-03-06 21:00 966

APAX Medical Introduces Cutting-Edge ADVATx Laser For Skin Rejuvenation

SINGAPORE, March 6, 2024 /PRNewswire/ -- APAX Medical & Aesthetics Clinic is proud to announce the introduction of the ADVATx laser treatment by Advalight in their offerings - a revolutionary laser system that targets both active acne and acne scars simultaneously. This innovative solution utilis...

2024-03-06 20:22 1646

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-03-06 19:33 1561

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Project will combat infant mortality rates and lessen fetal distress in East Africa TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City S...

2024-03-06 18:48 1665

Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...

2024-03-06 18:07 1538

MAG GROUP HOLDING RECORDS OVER AED 12.6 BILLION SALES IN 2023

DUBAI, UAE, March 6, 2024 /PRNewswire/ -- MAG Group Holding, the multinational conglomerate incorporating different companies across diverse sectors, announced the recording of AED 12.6 billion in sales for 2023 across its different real estate subsidiaries.

2024-03-06 18:00 2234

NIPPON EXPRESS HOLDINGS Acquires Stake in Instalimb, Japan's Startup Expanding 3D-printed Prosthetics Business Overseas

- Helping to Achieve Sustainable Societies Allowing All People to Lead Affluent and Fulfilling Lives - TOKYO, March 6, 2024 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. acquired an equity stake in Instalimb, Inc. (hereinafter "Instalimb"), which is expanding its 3D-printed prosthetics business ...

2024-03-06 14:00 1631

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment ofMark W...

2024-03-06 12:29 1636

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...

2024-03-06 08:59 2589
1 ... 9101112131415 ... 802

Week's Top Stories